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ABSTRACT
Non- pharmaceutical interventions (NPIs) have been 
widely implemented to mitigate the spread of COVID-19. 
We assessed the effect of NPIs on hospitalisations 
for pneumonia, influenza, COPD and asthma. This 
retrospective, ecological study compared the weekly 
incidence of hospitalisation for four respiratory 
conditions before (January 2016–January 2020) and 
during (February–July 2020) the implementation of 
NPI against COVID-19. Hospitalisations for all four 
respiratory conditions decreased substantially during 
the intervention period. The cumulative incidence of 
admissions for COPD and asthma was 58% and 48% 
of the mean incidence during the 4 preceding years, 
respectively.
INTRODUCTION
Non- pharmaceutical interventions (NPIs) have 
been the most important public health measure to 
mitigate the impact of the COVID-19 pandemic. 
NPIs implemented against COVID-19 are expected 
to reduce the transmission of other respiratory 
viruses, and early studies have reported a decrease 
in the incidence of viral respiratory infections.1 2
Thus, we assessed the incidence of hospitalisa-
tions due to pneumonia, influenza and chronic lung 
diseases during the COVID-19 pandemic in South 
Korea and compared it with the previous seasonal 




The daily number of hospitalisations was obtained 
from the National Health Insurance Service (NHIS) 
claims database. South Korea has a universal, single- 
payer healthcare coverage for all residents, and all 
covered costs are reimbursed by the NHIS. The 
cause of admission was captured from the primary 
diagnosis code using the International Statistical 
Classification of Diseases and Related Health Prob-
lems, 10th edition. The weekly incidence of hospi-
talisations was calculated by dividing the weekly 
number of admissions by the annual mid- year 
population, obtained from the Korean Statistical 
Information Service (http:// kosis. kr).
Study design and statistical analysis
This was a retrospective ecological study comparing 
the incidence of hospitalisation due to acute 
respiratory infections (pneumonia and influ-
enza) and chronic respiratory diseases (COPD 
and asthma) before and during the COVID-19 
pandemic. We also compared hospitalisations with 
the primary diagnosis of diabetic ketoacidosis or 
hyperosmolar hyperglycaemic state (DKA/HHS), 
intracranial haemorrhage (ICH), myocardial infarct 
(MI) and cancer to account for change in healthcare 
utilisation.
The baseline period was defined as January 
2016 to January 2020 and the intervention period 
as February to July 2020. Prediction models were 
constructed for each disease based on the incidence 
during the entire baseline period using an autore-
gressive integrated moving average (ARIMA). 
Parameters for the ARIMA models were selected 
using the ‘ auto. arima’ function in the ‘forecast’ 
package for R software (https:// pkg. robjhyndman. 
com/ forecast/). The weekly incidence of hospitali-
sations during the intervention period was visually 
compared with the 95% CI of the predicted values.
Furthermore, the cumulative incidence (CuI) 
during the intervention period (ie, sum of weekly 
incidences during the period) was compared with 
the 4- year mean CuI during the same months 
(February–July) of the baseline period. The differ-
ence in CuI was tested using a Poisson test. All tests 
were two- tailed and p values <0.05 were consid-
ered statistically significant. Statistical analyses 
were performed using R V.3.6.2 (R Foundation for 
Statistical Computing, Vienna, Austria).
RESULTS
Hospitalisations with the primary diagnosis of 
pneumonia decreased substantially during the inter-
vention period (figure 1). The CuI during the inter-
vention period was 0.47 times the CuI of the 4- year 
mean (95% CI 0.45 to 0.50; p<0.001; table 1). 
The weekly admissions for influenza were within 
95% CI of the predicted values; however, the 
CuI was significantly lower than the 4- year mean 
(0.22 times the 4- year mean; 95% CI 0.19 to 0.25; 
p<0.001). Hospitalisations due to pneumonia or 
influenza have decreased to comparable propor-
tions among patients with pre- existing COPD or 
asthma.
Hospital admissions due to COPD and asthma 
also decreased substantially. The CuIs for COPD 
and asthma admissions were 0.58 times (95% CI 
0.49 to 0.68; p<0.001) and 0.48 times (95% CI 
0.39 to 0.57; p<0.001) the mean baseline CuIs, 
respectively. The trend was consistent across all sex 
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and age groups (data not shown).
In contrast, hospital admissions for other acute (DKA/HHS, ICH 
and MI) and chronic (cancer) conditions during the intervention 
period were not significantly different from the predicted values or 
the 4- year means. Transient short- term decreases in admissions were 
observed from March through May 2020, but these ‘dips’ were not 
sustained and there was no significant difference in the CuI between 
the intervention and the baseline period (table 1).
DISCUSSION
Influenza and a substantial portion of pneumonia are primarily medi-
ated through droplet transmission. Personal hygiene and droplet 
precautions are well- known effective prevention measures for these 
infections.3 Since the early days of the COVID-19 epidemic, South 
Korea has thoroughly carried out social distancing, personal hygiene 
and universal use of face masks.4 In this study, the significant decrease 
in hospital admissions for influenza, pneumonia, COPD and asthma 
suggests the unintended benefits of these measures. This finding is 
consistent with previous reports that showed a decreased incidence 
of respiratory infections and influenza.1 2 5
It is noteworthy that not only the admissions for respiratory 
infections but also the overall admissions for COPD and asthma 
decreased substantially. Similar observations have been reported 
from Europe and the USA during the early stage of the COVID-19 
epidemic.6–8 Our results reaffirm those findings; also, our findings 
are unique as South Korea did not undergo ‘lockdown’ as many 
Figure 1 Weekly incidence of hospital admission per 1 000 000 population by primary diagnosis. Bold red lines denote the actual incidence during 
the intervention period; bold blue lines denote the predicted incidence; and dark and light blue shades denote the 80% and 95% CIs of the predicted 
incidence, respectively. Panels A–D show the hospitalisations due to respiratory diseases; panels E–H, hospitalisations for non- respiratory acute (E–G) 
and chronic (H) conditions.
Table 1 Cumulative incidence of hospital admission from February through July in 2020 versus 2016–2019
Disease
Cumulative incidence, February–July
(per 1 000 000)
Rate ratio (95% CI) P value
Mean
(2016–2019) Observed (2020)
Pneumonia 3965.29 1872.59 0.47 (0.45 to 0.50) <0.001
  Patients with COPD 28 304.95 15 182.24 0.54 (0.53 to 0.55) <0.001
  Patients with asthma 3196.58 1200.35 0.38 (0.35 to 0.40) <0.001
Influenza 1366.09 299.33 0.22 (0.19 to 0.25) <0.001
  Patients with COPD 1355.74 363.06 0.27 (0.24 to 0.30) <0.001
  Patients with asthma 554.65 79.56 0.14 (0.11 to 0.18) <0.001
COPD 435.11 251.70 0.58 (0.49 to 0.68) <0.001
Asthma 353.16 168.13 0.48 (0.39 to 0.57) <0.001
Diabetic ketoacidosis/hyperosmolar hyperglycaemic state 54.94 55.25 1.02 (0.69 to 1.51) >0.999
Intracranial haemorrhage 329.17 305.69 0.93 (0.79 to 1.09) 0.361
Myocardial infarct 286.37 280.00 0.98 (0.82 to 1.15) 0.801
Cancer 1914.28 1922.59 1.00 (0.94 to 1.07) 0.910
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European countries did and we demonstrated that the decrease was 
sustained for at least 6 months. Conversely, hospital admissions due 
to other acute (DKA/HHS, ICH and MI) and chronic (cancer) condi-
tions did not decrease, which shows this was not attributable to an 
alteration in healthcare- seeking behaviour. Our findings suggest that 
the decrease in admissions due to COPD and asthma might be asso-
ciated with the decrease in respiratory infections, which are the most 
common triggers for acute exacerbation of COPD and asthma.9 10
This study has some limitations. First, we identified the cause of 
admission from the primary diagnosis code used for billing. However, 
there is no reason to suspect a change of coding practices during the 
intervention period. Second, we could not directly confirm from the 
claims database that the reduction in respiratory infections led to 
the decrease in admissions among patients with COPD and asthma. 
There remains a possibility that the decrease in admissions resulted 
from the alteration in healthcare- seeking behaviour, although no 
significant change was observed in admissions for non- respiratory 
conditions. In such case, the decrease in hospitalisation may lead to 
delayed care and increased mortality later.
In conclusion, we found that the hospital admission rates for 
respiratory infections and chronic lung diseases decreased signifi-
cantly after the implementation of NPIs against COVID-19, despite 
the lack of change in admission rates for non- respiratory conditions.
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